This listing of claims will replace all prior versions, and listings, of claims in the application (note that amendments are **highlighted in bold**):

Listing of Claims:

1. (currently amended) A compound of formula I



I

or a pharmaceutically acceptable salt or solvate thereof, wherein

n is 0 to 4;

p is 0 to 4;

q is 0 to 5;

X is selected from the group consisting of hydrogen, alkoxy, alkyl, aryl, cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, haloalkoxy, haloalkyl, halogen, heteroalkyl, heteroaryl, $-CF_3$, -CN, $-C(O)N(R^2)_2$, $-C(O)OR^2$, $-N(R^2)_2$, $-NHC(O)R^2$, $-NR^2C(O)OR^2$, $-NR^2C(O)N(R^2)_2$, $-NO_2$, $-NC(=N-CN)NHR^2$, $-OCF_2H$, $-OCF_3$, -OH and $-S(O_2)N(R^2)_2$, with the proviso that when n is 2, 3 or 4, the X moieties can be the same or different and are independently selected from the group listed above;

Y is selected from the group consisting of hydrogen, alkoxy, alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, halogen, heteroalkyl, heteroaryl, -O-cycloalkyl, $-CF_3$, -CN, $-C(O)OR^2$, $-C(O)R^2$, $-N(R^2)_2$, $-OCF_3$, $-OCF_2H$ and -OH, with the proviso that:

when p is 2, 3 or 4, the Y moieties can be the same or different and are independently selected from the group listed above; or

when p is 2, the Y moieties can form a cyclic ring of 3 to 7 ring atoms of which 1-2 may be a heteroatom;

Z is selected from the group consisting of hydrogen, alkoxy, alkyl, cycloalkyl, cycloalkenyl, halogen, heteroalkyl, heteroaryl, heterocyclyl, heterocyclenyl, -O-cycloalkyl, $-CF_3$, -CN, $-C(O)OR^2$, $-N(R^2)_2$, $-OCF_3$, $-OCF_2H$, -OH and $-S(O_2)R^2$, with the proviso that when q is 2, 3, 4 or 5, the Z moieties can be the same or different and are independently selected from the group listed above;

R^1 is selected from the group consisting of hydrogen, alkoxy, alkyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocyclyl, heterocyclenyl, and-$N(R^2)_2$;

R^2 is selected from the group consisting of hydrogen, alkoxy, alkyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocyclyl, heterocyclenyl, and hydroxyalkyl;

L^1 is selected from the group consisting of a covalent bond, $-C(F_2)-$, $-(CH(OR^2))-$, -C(O)-, -C(O)N(H)-, $-C(=N-OR^2)-$, $-C(=NR^2)-$, -C(=N-CN)-, $-C(R^2)_2-$, $-N(R^2)-$, -N(H)C(O)-, $-N(R^2)S(O_2)-$, -O-, -OC(O)-, -C(O)O-, -S-, $-S(O_2)-$, -S(O)- and $-S(O_2)N(R^2)-$, with the proviso that when L^1 is a covalent bond, M^1 is directly attached to the phenyl carbon marked A;

L^2 is selected from the group consisting of a covalent bond, $-C(R^2)_2-$, $-C(=N-OR^2)-$, -C(O)-, -C(O)N(H)-, -C(O)O-, -OC(O)-, -N(H)C(O)-, $-NHS(O_2)-$, $-N(R^2)-$, -O-, -S-, -S(O)-, $-S(O_2)-$ and $-S(O_2)N(R^2)-$, with the proviso that when L^2 is a covalent bond, M^1 is directly attached to M^2;

M^1 is aryl, cycloalkyl, heteroaryl or heterocycloalkyl;

and

M^2 is alkyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocyclyl, heterocyclenyl, $-C(O)R^2$, $-C(O)OR^2$, $-N(R^2)_2$ or $-S(O_2)R^2$;

with the provisos that:

i) when M^2 is $-N(R^2)_2$, L^2 is a covalent bond, $-CH_2-$, -C(O)- or $-S(O_2)-$ and Z is absent;

ii) when M^2 is $-C(O)R^2$ or $-C(O)OR^2$, L^2 is a covalent bond, $-CH_2-$, -NH- or -N(alkyl)- and Z is absent;

iii) when M^2 is $-S(O_2)R^2$, L^2 is a covalent bond, $-CH_2-$, -NH- or -N(alkyl)- and Z is absent;

and

iv) the two R^2 moieties of $-N(R^2)_2$ and $-C(R^2)_2-$ are the same or different and are independently selected, or the two R^2 of $-N(R^2)_2$ are joined together and with the nitrogen to which they are attached to form a heterocyclic ring having 3 to 7 ring atoms optionally containing additionally one or more N or O atoms wherein said additional N can be optionally substituted with R^2;

wherein each of said alkoxy, alkyl, aralkyl, aryl, cycloalkyl, cycloalkenyl, heteroaralkyl, heteroaryl, heterocyclyl, and heterocyclenyl in the definitions above can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, $-CF_3$, alkoxy, -CN, $-C(O)N(R^2)_2$, $-C(O)OR^2$, $-C(O)R^2$, $-NC(O)R^2$, $-NR^2C(O)OR^2$, $-NR^2C(O)N(R^2)_2$, $-NC(=N-CN)NHR^2$, $-NO_2$, $-N(R^2)_2$, $-OCF_2H$, $-OCF_3$, -OH, $-S(O_2)R^2$ and $-S(O_2)N(R^2)_2$;

with the proviso that when R^1 is alkyl, said R^1 is not substituted with $-NC(O)R^2$, $-NR^2C(O)OR^2$, $-NR^2C(O)N(R^2)_2$ or $-N(R^2)_2$.

2. (original) The compound according to claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein

M^1 is aryl, heteroaryl or heterocycloalkyl;

and

M^2 is aryl, cycloalkyl, heteroaryl, or heterocyclyl.

3. (original) The compound according to claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein X is selected from the group consisting of hydrogen, alkoxy, $-CF_3$, haloalkoxy, halogen, $-OCF_3$, $-OCF_2H$ and -OH.

4. (original) The compound according to claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein Y is selected from the group consisting of hydrogen, alkoxy, alkyl, $-CF_3$, $-C(O)OR^2$, cycloalkyl, halogen, $-N(R^2)_2$, $-OCF_3$, -O-cycloalkyl and -OH.

5. (original) The compound according to claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein Z is selected from the group consisting of hydrogen, alkoxy, alkyl, $-CF_3$, $-C(O)OR^2$, halogen, heterocyclyl, $-N(R^2)_2$, $-OCF_3$, -O-cycloalkyl and -OH.

6. (original) The compound according to claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein R^1 is selected from the group consisting of hydrogen, alkoxy, alkyl, cycloalkyl and $-N(R^2)_2$.

7. (original) The compound according to claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein R^2 is selected from the group consisting of hydrogen, alkyl, aryl, cycloalkyl and heterocycloalkyl.

8. (original) The compound according to claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein L^1 is selected from the group consisting of $-C(R^2)_2-$, $-N(R^2)S(O_2)-$, $-N(R^2)-$, $-S(O_2)-$ and $-S(O_2)N(R^2)-$.

9. (original) The compound according to claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein L^2 is selected from the group consisting of a covalent bond, $-C(R^2)_2-$, $-N(R^2)S(O_2)-$, $-N(R^2)-$, $-S(O_2)-$ and $-S(O_2)N(R^2)-$.

10. (original) The compound according to claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein M^1 is aryl, heteroaryl or heterocyclyl.

11. (original) The compound according to claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein M^2 is aryl, cycloalkyl, heteroaryl, or heterocyclyl.

12. (original) The compound according to claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein

X is selected from the group consisting of hydrogen, alkoxy, $-CF_3$, haloalkoxy, halogen, $-OCF_3$, $-OCF_2H$ and -OH;

Y is selected from the group consisting of hydrogen, alkoxy, alkyl, $-CF_3$, $-C(O)OR^2$, cycloalkyl, halogen, $-N(R^2)_2$, $-OCF_3$, -O-cycloalkyl and -OH;

Z is selected from the group consisting of hydrogen, alkoxy, alkyl, $-CF_3$, $-C(O)OR^2$, halogen, heterocyclyl, $-N(R^2)_2$, $-OCF_3$, -O-cycloalkyl and -OH;

R^1 is selected from the group consisting of hydrogen, alkoxy, alkyl, cycloalkyl and $-N(R^2)_2$;

R^2 is selected from the group consisting of hydrogen, alkyl, aryl, cycloalkyl and heterocyclyl;

L^1 is selected from the group consisting of $-C(R^2)_2-$, $-N(R^2)-$, $-S(O_2)-$ and $-S(O_2)N(R^2)-$;

L^2 is selected from the group consisting of a covalent bond, $-C(R^2)_2-$, $-N(R^2)S(O_2)-$, $-N(R^2)-$, $-S(O_2)-$ and $-S(O_2)N(R^2)-$;

M^1 is aryl, heteroaryl or heterocyclyl;

M^2 is aryl, cycloalkyl, heteroaryl, or heterocyclyl;

with the provisos that:

the two R^2 moieties of $N(R^2)_2$ and $C(R^2)_2$- are the same or different and are independently selected, wherein each R^2 of $N(R^2)_2$ are joined together and with the nitrogen to which they are attached form a heterocyclic ring having 3 to 7 ring atoms;

wherein each of said alkoxy, alkyl, aralkyl, aryl, cycloalkyl, heteroaralkyl, heteroaryl and heterocyclyl in the definitions above can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkoxy, $-CF_3$, -CN, $-C(O)N(R^2)_2$, $-C(O)OR^2$, $-C(O)R^2-$, $-NC(O)R^2$, $-NR^2C(O)OR^2$, $-NR^2C(O)N(R^2)_2$, $-NC(=N-CN)NHR^2$, $-NO_2$, $-N(R^2)_2$, $-OCF_2H$, $-OCF_3$, -OH, $-S(O_2)R^2$ and $-S(O_2)N(R^2)_2$.

13. (original) The compound according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein

n is 1;

X is hydrogen and -OH;

Y is selected from the group consisting of hydrogen, alkoxy, alkyl, $-CF_3$, $-C(O)OR^2$, cycloalkyl, halogen, $-N(R^2)_2$, $-OCF_3$ and -OH;

Z is selected from the group consisting of hydrogen, alkoxy, alkyl, $-CF_3$, $-C(O)OR^2$, halogen, heterocyclyl, $-N(R^2)_2$, $-OCF_3$, -O-cycloalkyl and -OH;

R^1 is selected from the group consisting of hydrogen, alkoxy, alkyl, cycloalkyl and $-N(R^2)_2$;

R^2 is selected from the group consisting of hydrogen, alkyl, aryl, cycloalkyl and heterocyclyl;

L^1 is selected from the group consisting of $-C(O)-$, $-C(R^2)_2-$ and $-S(O_2)-$;

L^2 is selected from the group consisting of a covalent bond, $-C(R^2)_2-$, $-C(O)-$ and $-S(O_2)-$;

M^1 is aryl, heteroaryl or heterocyclyl;

and

M^2 is aryl, cycloalkyl, heteroaryl, or heterocyclyl.

14. (original) The compound according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein

n is 1;

X is hydrogen and -OH;

Y is selected from the group consisting of hydrogen, alkoxy, alkyl, $-C(O)OR^2$, cycloalkyl, $-CF_3$, halogen, $-OCF_3$ and -OH;

Z is selected from the group consisting of hydrogen, alkoxy, alkyl, $-CF_3$, halogen, $-OCF_3$, -O-cycloalkyl and -OH;

R^1 is selected from the group consisting of hydrogen, alkoxy, alkyl, cycloalkyl and $-N(R^2)_2$;

R^2 is selected from the group consisting of hydrogen, alkyl, aryl and cycloalkyl;

L^1 and L^2 are the same or different and are independently $-C(R^2)_2-$ or $-S(O_2)-$;

M^1 is aryl or heteroaryl;

and

M^2 is aryl, cycloalkyl, heteroaryl or heterocyclyl.

15. (original) The compound according to claim 1 having the formula II:



II

or a pharmaceutically acceptable salt thereof, wherein

Y is selected from the group consisting of hydrogen, alkoxy, alkyl, $-CF_3$, -CN $-C(O)OR^2$, cycloalkyl, halogen, $-N(R^2)_2$, $-OCF_3$ and –OH, with the proviso that when p is 2, the Y moieties can form a cyclic ring of 3 to 7 ring atoms of which 1-2 may be a heteroatom;

Z is selected from the group consisting of hydrogen, alkoxy, alkyl, $-CF_3$, $-C(O)OR^2$, halogen, heterocyclyl, $-N(R^2)_2$, $-OCF_3$, -O-cycloalkyl and -OH;

R^1 is selected from the group consisting of hydrogen, alkoxy, alkyl, cycloalkyl, heterocyclyl and $-N(R^2)_2$;

R^2 is selected from the group consisting of hydrogen, alkyl, aryl and cycloalkyl;

L^1 is a covalent bond, $-C(R^2)_2$-or $-S(O_2)$-;

M^1 is aryl, indolyl, oxabicycloheptenyl or furanyl;

and

M^2 is aryl, cycloalkyl, heteroaryl or heterocyclyl.

16. (original) The compound according to claim 15 having the formula II, or a pharmaceutically acceptable salt thereof, wherein R^1, L^1, M^1, M^2, Y and Z are as set forth in the following table:

	R^1	L^1	M^1-Y	M^2-Z	Y	Z
	$-CH(CH_3)_2$	$-CH_2-$			$-CF_3$	F

	R^1	L^1	M^1-Y	M^2-Z	Y	Z
	$-CH(CH_3)_2$	$-CH_2-$			$-CF_3$	
	$-CH(CH_3)_2$	$-CH_2-$			$-OCF_3$	F
	$-CH(CH_3)_2$	$-CH_2-$			$-OCF_3$	$-NH(CH_2)_2OH$
	$-CH(CH_3)_2$	$-S(O_2)-$			$-OCF_3$	$-CH_3$
	$-CH(CH_3)_2$	$-S(O_2)-$			$-OCF_3$	F

	R^1	L^1	M^1-Y	M^2-Z	Y	Z
	$-CH(CH_3)_2$	$-S(O_2)-$			$-OCF_3$	H
	$-CH(CH_3)_2$	$-S(O_2)-$			H	F
	$-CH(CH_3)_2$	$-S(O_2)-$			$-OCF_3$	H
	$-CH(CH_3)_2$	$-CH_2-$			H	F
		$-S(O_2)-$			Cl	F
	$-CH(CH_3)_2$	$-S(O_2)-$			H	H

	R^1	L^1	M^1-Y	M^2-Z	Y	Z
	$-CH(CH_3)_2$	$-S(O_2)-$			$N(CH_3)_2$	F
	$-CH(CH_3)_2$	$-S(O_2)-$			H	H
	$-N(CH_3)_2$	$-S(O_2)-$			$-CH(CH_3)_2$	H
	$-CH(CH_3)_2$	$-S(O_2)-$			$-N(CH_3)_2$	H
	$-CH(CH_3)_2$	$-S(O_2)-$			$-CH(CH_3)_2$	H
	$-CH(CH_3)_2$	$-S(O_2)-$			OH	F

	R^1	L^1	M^1-Y	M^2-Z	Y	Z
	$-CH(CH_3)_2$	$-S(O_2)-$				F
	$-CH(CH_3)_2$	Covalent bond			$-CH(CH_3)_2$	$-CH_3$
	$-CH(CH_3)_2$	$-S(O_2)-$				H
		$-S(O_2)-$			$-CH(CH_3)_2$	H
		$-S(O_2)-$			$-OCH_3$	H
	$-CH(CH_3)_2$	$-S(O_2)-$			$-CH(CH_3)_2$	H

	R^1	L^1	M^1-Y	M^2-Z	Y	Z
	$-CH(CH_3)_2$	$-S(O_2)-$			$-CH(CH_3)_2$	H
		$-S(O_2)-$				H
		$-S(O_2)-$				H
	$-CH(CH_3)_2$	$-S(O_2)-$			-CN	H
	$-CH(CH_3)_2$	$-S(O_2)-$				H
	$-CH(CH_3)_2$	$-S(O_2)-$			$-CF_3$	H
	$-CH(CH_3)_2$	$-S(O_2)-$			H	F

	R^1	L^1	M^1-Y	M^2-Z	Y	Z
	$-CH(CH_3)_2$	$-S(O_2)-$			$-OCH_3$	F
	$-CH(CH_3)_2$	$-S(O_2)-$			$-OCH_3$	H
		$-S(O_2)-$			$-OCH_3$	F
		$-S(O_2)-$				H
	$-CH(CH_3)_2$	$-S(O_2)-$			$-CH(CH_3)_2$	H
	$-CH(CH_3)_2$	$-S(O_2)-$			$-OCH(CH_3)_2$	F
	$-CH(CH_3)_2$	$-S(O_2)-$			$-OCH(CH_3)_2$	H

	R^1	L^1	M^1-Y	M^2-Z	Y	Z
	$-OCH(CH_3)_2$	$-S(O_2)-$			$-CH(CH_3)_2$	H
	$-CH(CH_3)_2$	$-S(O_2)-$			$-OCH(CH_3)_2$	$-COOCH_3$
	$-CH(CH_3)_2$	$-S(O_2)-$			H	F
	$-CH(CH_3)_2$	$-S(O_2)-$			H	H
	$-CH(CH_3)_2$	$-S(O_2)-$			H	H
	$-CH(CH_3)_2$	$-S(O_2)-$			$-CF_3$	H
	$-CH(CH_3)_2$	$-S(O_2)-$			H	H

17. (original) The compound according to claim 1 having the formula III:



III

or a pharmaceutically acceptable salt thereof, wherein

Y is selected from the group consisting of hydrogen, alkoxy, alkyl, $-CF_3$, cycloalkyl, halogen, $-OCF_3$ and -OH;

Z is selected from the group consisting of hydrogen, alkyl, $-CF_3$, halogen,$-N(R^2)_2$, $-OCF_3$ and -OH;

and

M^2 is aryl or heteroaryl.

18. (original) The compound according to claim 1 having the formula IV



IV

or a pharmaceutically acceptable salt thereof, wherein

Y is selected from the group consisting of hydrogen, alkoxy, alkyl, cycloalkyl and $-OCF_3$;

Z is selected from the group consisting of hydrogen, alkyl, $-CF_3$, halogen, $-N(R^2)_2$, $-OCF_3$ and -OH;

and

M^2 is aryl or heteroaryl.

19. (original) The compound according to claim 1 having the formula V



V

or a pharmaceutically acceptable salt thereof, wherein

Z is selected from the group consisting of hydrogen, $-CF_3$, halogen, $-OCF_3$ and -OH;

and

M^2 is aryl or heteroaryl.

20. (original) The compound of claim 1 having the formula VI



VI

or a pharmaceutically acceptable salt thereof, wherein

M^2 is aryl or heteroaryl;

and

Z is selected from the group consisting of hydrogen, alkyl, halogen, $-CF_3$, $-N(R^2)_2$, -OH and $-OCF_3$.

21. (original) The compound of claim 1 having the formula:



or

or a pharmaceutically acceptable salt thereof.

22. (original) A pharmaceutical composition comprising an effective amount of at least one compound according to claim 1 and a pharmaceutically acceptable carrier.

23. (original) A pharmaceutical composition comprising an effective amount of at least one compound according to claim 16 and a pharmaceutically acceptable carrier.

Claims 24-29 (canceled)

30. (original) A process for making a pharmaceutical composition comprising combining at least one compound of claim 1 and at least one pharmaceutically acceptable carrier.

31. (original) A process for making a pharmaceutical composition comprising combining at least one compound of claim 16 and at least one pharmaceutically acceptable carrier.

Claims 32-57 (canceled)